Ferriprox
Payments companies reported to CMS as associated with Ferriprox. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ferriprox, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ferriprox
These are the largest totals companies reported as associated with Ferriprox. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sherif Badawy | Chicago, IL | Pediatric Hematology-Oncology | $38,710.37 |
| Amer Zeidan | New Haven, CT | Hematology & Oncology | $17,400.00 |
| Andrew Campbell | Ann Arbor, MI | Pediatric Hematology-Oncology | $16,513.21 |
| Sujit Sheth | New York, NY | Pediatric Hematology-Oncology | $15,521.82 |
| Stephanie Fritch Lilla | Minneapolis, MN | Pediatric Hematology-Oncology | $14,656.28 |
| Nirmish Shah | Durham, NC | Internal Medicine | $13,225.32 |
| Julie Kanter Washko | Birmingham, AL | Pediatric Hematology-Oncology | $11,390.72 |
| Alex George | Winston Salem, NC | Pediatric Hematology-Oncology | $8,975.34 |
| Jeffrey Lipton | New Hyde Park, NY | Pediatric Hematology-Oncology | $8,534.12 |
| Geetha Puthenveetil | Los Angeles, CA | Pediatric Hematology-Oncology | $8,500.78 |
Prescribed Ferriprox?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.